Lupin strengthens branded drug business in US

The drug, Methergine, is the only FDA approved oral uterotonic and Lupin has created of a specialized sales force to drive product sales

Lupin has strengthened its branded drug portfolio in the US market with the relaunch of a drug to control postpartum hemorrhage (post delivery blood loss).

The drug Methergine (methylergonovine maleate) is the only FDA approved oral uterotonic and Lupin has created of a specialized sales force to drive product sales.

Lupin earns about 45 per cent of its revenue from the US market and has been focusing on developing specialty and branded products. Till now the drug maker has five branded products in the market and has now decided to relaunch two drugs from subsidiary Gavis portfolio (Methergine and Methylphenidate) as brands.

Read more from our special coverage on "LUPIN"

• Lupin launches generic Femhrt tablets in US
• Lupin gains on launch of first product from GAVIS pipeline in the US
• Lupin launches generic insomnia drug in US
• Stocks drop for second day as Lupin falls most since 08
• Lupin gets three observations from USFDA for Mandideep plant

"As Gavis is the sole supplier of these two products, management believes that these products can contribute $30-40mn incremental business to Lupin's branded portfolio by FY18," Bank of America Merrill Lynch said in a research note.